Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Foresee Pharmaceuticals Co's enterprise value is NT$12,106.4 Mil.
Foresee Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$153.8 Mil. Therefore, Foresee Pharmaceuticals Co's EV-to-EBITDA for today is 78.70.
The historical rank and industry rank for Foresee Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6576'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -143.11 Med: -13.74 Max: 81.41
Current: 78.7
During the past 12 years, the highest EV-to-EBITDA of Foresee Pharmaceuticals Co was 81.41. The lowest was -143.11. And the median was -13.74.
ROCO:6576's EV-to-EBITDA is ranked worse than 93.84% of 730
companies
in the Drug Manufacturers industry
Industry Median: 13.47
vs ROCO:6576: 78.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Foresee Pharmaceuticals Co (ROCO:6576) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Foresee Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Foresee Pharmaceuticals Co's share price for today is NT$80.10.
Foresee Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's EV-to-EBITDA falls into.
Foresee Pharmaceuticals Co's current Enterprise Value is NT$12,106.4 Mil.
Foresee Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$153.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foresee Pharmaceuticals Co (ROCO:6576) has a EV-to-EBITDA of 78.70 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Foresee Pharmaceuticals Co. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #685 out of 730 companies in the Drug Manufacturers industry, placing it in the top 93.8%.
Is Foresee Pharmaceuticals Co's EV-to-EBITDA too high?
Foresee Pharmaceuticals Co's current EV-to-EBITDA is 78.70. The Drug Manufacturers industry median EV-to-EBITDA is 13.47. Foresee Pharmaceuticals Co's value of 78.70 is 484.3% above this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #685 out of 730 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #685 out of 730 companies for EV-to-EBITDA. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.47. Foresee Pharmaceuticals Co's value of 78.70 is 484.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.47, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current EV-to-EBITDA of 78.70 is 484.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Foresee Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current EV-to-EBITDA is 78.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$92.17, compared to a current price of NT$80.10 — trading 13.1% below its estimated fair value. The current EV-to-EBITDA is 78.70 and 484.3% above the Drug Manufacturers industry median of 13.47. Foresee Pharmaceuticals Co's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current EV-to-EBITDA is 78.70 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$80.10 is trading 13.1% below its estimated GF Value™ of NT$92.17.
GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for ROCO:6576:
EV-to-EBITDA: 78.70
GF Value™: NT$92.17 vs. price of NT$80.10 (13.1% below fair value)
Industry Position: 484.3% above the Drug Manufacturers median (#685 of 730)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
67GF Score
Get the complete analysis for ROCO:6576
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
